Focal treatment-resistant epilepsy improves over time, but seizure reduction appears to be unrelated to specific medications ...

The type of seizure you have depends on what area and how much of the brain's electrical activity is affected.

About one-third of patients with focal epilepsy, a common form of the neurological disorder, are believed to respond poorly ...

The new study, part of the international Human Epilepsy Project, tracked nearly 150 adults who were deemed ...

Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures The CORE-VNS 36-month data analysis reaffirms the effectiveness of VNS Therapy ...

A phase 2a trial of Rapport Therapeutics’ focal onset seizure drug candidate has hit its primary endpoint, sending shares in the biotech up more than 157% in premarket trading. The study enrolled 30 ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. A positive readout of a Rapport Therapeutics seizure medicine in a ...

Praxis Precision Medicines, Inc. (($PRAX)) announced an update on their ongoing clinical study. Praxis Precision Medicines, Inc. is conducting a ...

Antiseizure medications help the majority of people with focal epilepsy, a common form of the neurological disorder. Yet most will still have episodes for at least a year after their treatment begins, ...